S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.31
+1.63
+9.77%
AGIO · Agios Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Agios Pharmaceuticals Inc (AGIO)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$37.21
+0.54
(+1.47%)
● At close: October 21 at 4:00:00 PM EDT
$36.50
-0.68
(-1.83%)
Pre-Market:
4:08:32 AM EDT
DAY'S RANGE
$37.21
$36.63
$37.57
52-WEEK RANGE
$37.21
$22.24
$46.00
What's happening
- AGIO is up 1.47% today, trading at $37.21. — Live quote
- Volume today (59,420) is well below its 3-month average of 1,136,130. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.69 actual vs. $-1.70 estimated (+0.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 7
Hold 4
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
AGIO
+36.59%
vs S&P 500
+23.22%
1-YEAR RETURN
AGIO
-14.43%
vs S&P 500
-29.60%
6-MONTH RETURN
AGIO
+5.81%
3-MONTH RETURN
AGIO
+3.13%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.69
Est. $-1.70
BEAT +0.7%
2026-04-26 (Q1 2026)
$-1.69
Est. $-1.84
BEAT +8.0%
2026-01-26 (Q4 2025)
$-1.86
Est. $-1.99
BEAT +6.3%
2025-10-26 (Q3 2025)
$-1.78
Est. $-1.94
BEAT +8.1%
Valuation Measures & Ratios
Enterprise Value4$2.09B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)22.24
Price / Book72.15
EV4 / Revenue21.23
EV4 / EBITDA3.30
Profit Margin-418.24%
Operating Margin-466.78%
Return on Equity (ROE8)-35.67%
Return on Assets (ROA9)-33.06%
Avg Volume (3M)1,136,130
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.21B | $1.98B | $2.33B | $1.93B | $1.69B |
| P/E | -5.33 | -4.91 | 3.63 | 2.96 | 2.48 |
| Price/Sales | 24.37 | 36.20 | 54.25 | 49.74 | 48.92 |
| Price/Book | 2.16 | 1.79 | 1.82 | 1.41 | 1.15 |
| EV/Revenue | 23.27 | 34.13 | 52.10 | 47.65 | 46.63 |
| ROE | -40.47% | -36.41% | 50.08% | 47.50% | 46.43% |
| ROA | -37.46% | -34.08% | 46.41% | 44.21% | 43.78% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short7,016,166
Change from Prior Settlement-7.16%
% of Float—
Days to Cover (Short Ratio)6.44
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 259.2% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-08-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -418.2%. Finnhub fundamentals ↗
- Trailing 52-week price return is -14.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on AGIO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.7M | $20.7M | $12.9M | $12.5M | $8.7M | $9.0M | $8.6M | $8.2M |
| Operating income | -$110.6M | -$110.0M | -$116.9M | -$127.1M | -$106.6M | -$102.8M | -$105.8M | -$92.1M |
| Net income | -$100.7M | -$99.1M | -$103.4M | -$112.0M | -$89.3M | $947.9M | -$96.1M | -$81.5M |
| EPS (diluted) | $-1.69 | $-1.69 | $-1.78 | $-1.93 | $-1.55 | $16.22 | $-1.69 | $-1.45 |
| EPS (basic) | $-1.69 | $-1.69 | $-1.78 | $-1.93 | $-1.55 | $16.65 | $-1.69 | $-1.45 |
| Operating margin | -$247 | -$530 | -$907 | -$1.0K | -$1.2K | -$1.1K | -$1.2K | -$1.1K |
| Net margin | -$225 | -$478 | -$803 | -$899 | -$1.0K | $10.6K | -$1.1K | -$996 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.11B | $1.18B | $1.30B | $1.39B | $1.47B | $1.56B | $1.66B | $1.79B |
| Total liabilities | $82.4M | $75.9M | $104.1M | $101.4M | $101.7M | $89.0M | $122.2M | $165.1M |
| Stockholders' equity | $1.03B | $1.11B | $1.19B | $1.28B | $1.37B | $1.47B | $1.54B | $1.63B |
| Total current assets | $717.7M | $834.8M | $942.1M | $1.03B | $1.02B | $968.6M | $965.6M | $1.07B |
| Total current liabilities | $70.2M | $58.8M | $82.2M | $74.8M | $70.4M | $52.4M | $81.2M | $119.5M |
| Cash & equivalents | $99.6M | $113.6M | $89.1M | $92.7M | $80.9M | $79.0M | $76.2M | $253.7M |
| Inventory | $35.8M | $35.1M | $32.9M | $32.0M | $30.8M | $29.6M | $27.6M | $26.4M |
| Property, plant & equipment | $9.9M | $10.6M | $10.8M | $10.7M | $10.6M | $11.1M | $11.7M | $11.8M |
| Other non-current assets | $9.7M | $3.9M | $3.9M | $3.9M | $3.9M | $4.7M | $4.7M | $4.1M |
| Accounts payable | $16.3M | $13.7M | $18.4M | $19.6M | $17.5M | $13.7M | $16.6M | $17.1M |
| Accrued liabilities | $34.6M | $26.3M | $45.5M | $37.2M | $35.3M | $20.8M | $46.9M | $33.3M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $240.0K | $90.0K | $90.0K | $90.0K | $101.0K | $880.0K | $880.0K | $1.2M |
| Common stock & paid-in capital | — | — | — | — | — | — | — | — |
| Retained earnings | -$761.5M | -$660.8M | -$561.7M | -$453.7M | -$350.2M | -$238.2M | -$148.9M | -$52.4M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$57.3M | -$118.9M | -$96.2M | -$88.2M | -$77.1M | -$111.5M | -$133.2M | -$84.2M |
| Investing cash flow | $40.2M | $141.3M | $90.1M | $95.6M | $79.0M | $112.6M | -$49.2M | $250.8M |
| Financing cash flow | $3.1M | $2.1M | $2.6M | $4.4M | $65.0K | $1.6M | $4.8M | $2.6M |
| Free cash flow | -$58.5M | -$119.7M | -$97.3M | -$89.7M | -$78.0M | -$112.3M | -$134.1M | -$84.6M |
| Capital expenditures | $1.2M | $769.0K | $1.1M | $1.6M | $875.0K | $766.0K | $967.0K | $419.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $15.9M | $15.5M | $14.1M | $12.4M | $14.7M | $11.4M | $10.9M | $11.1M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | $4.0M | $5.6M | $5.5M | $43.0K | $1.6M | -$765.0K | $991.0K | -$644.0K |
| Change in inventory | -$4.9M | $2.2M | $886.0K | $1.2M | $1.2M | $2.0M | $1.2M | $2.5M |
| Change in accounts payable | $3.1M | -$5.0M | -$1.1M | $1.8M | $3.9M | -$2.8M | -$756.0K | $7.1M |
| Purchases of investments | $151.6M | $148.2M | $161.1M | $175.0M | $130.8M | $174.9M | $198.3M | $995.5M |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $54.0M | $36.5M | $26.8M | $14.2M | $0 |
| Operating income | -$472.1M | -$425.7M | -$391.5M | -$389.0M | -$378.4M |
| Net income | -$412.8M | $673.7M | -$352.1M | -$231.8M | $1.60B |
| EPS (diluted) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 |
| EPS (basic) | $-7.12 | $11.86 | $-6.33 | $-4.23 | $26.55 |
| Operating margin | -$874 | -$1.2K | -$1.5K | -$2.7K | — |
| Net margin | -$764 | $1.8K | -$1.3K | -$1.6K | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $1.30B | $1.66B | $937.1M | $1.24B | $1.44B |
| Total liabilities | $104.1M | $122.2M | $126.1M | $137.9M | $145.8M |
| Stockholders' equity | $1.19B | $1.54B | $811.0M | $1.10B | $1.29B |
| Total current assets | $942.1M | $965.6M | $833.8M | $832.8M | $1.06B |
| Total current liabilities | $82.2M | $81.2M | $68.0M | $62.6M | $59.8M |
| Cash & equivalents | $89.1M | $76.2M | $88.2M | $139.3M | $203.1M |
| Inventory | $32.9M | $27.6M | $19.1M | $8.5M | $0 |
| Property, plant & equipment | $10.8M | $11.7M | $15.4M | $23.0M | $28.9M |
| Other non-current assets | $3.9M | $4.7M | $4.1M | $4.0M | $2.9M |
| Accounts payable | $18.4M | $16.6M | $9.8M | $18.6M | $16.7M |
| Accrued liabilities | $45.5M | $46.9M | $43.2M | $30.4M | $32.0M |
| Deferred revenue (current) | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Other non-current liabilities | $90.0K | $880.0K | $1.2M | $3.3M | $0 |
| Common stock & paid-in capital | — | — | — | — | $71.0K |
| Retained earnings | -$561.7M | -$148.9M | -$822.6M | -$470.6M | -$238.8M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$373.0M | -$389.8M | -$296.1M | -$309.5M | -$407.3M |
| Investing cash flow | $377.2M | $363.4M | $239.6M | $243.3M | $1.25B |
| Financing cash flow | $8.7M | $14.4M | $5.4M | $2.4M | -$765.8M |
| Free cash flow | -$377.3M | -$391.5M | -$297.1M | -$314.4M | -$413.1M |
| Capital expenditures | $4.3M | $1.7M | $999.0K | $4.9M | $5.7M |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $52.6M | $42.8M | $44.8M | $49.3M | $53.5M |
| Deferred income taxes | — | — | — | — | — |
| Change in accounts receivable | $6.5M | $1.3M | $604.0K | $2.2M | $0 |
| Change in inventory | $5.3M | $8.5M | $10.6M | $8.5M | $0 |
| Change in accounts payable | $1.7M | $6.6M | -$8.7M | $3.4M | $1.9M |
| Purchases of investments | $641.8M | $1.54B | $417.9M | $1.03B | $1.38B |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding AGIO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-02 to 2026-08-04
Recent transactions
- Insiders have net sold 34,007 shares over the last 182 days, across 0 purchases and 2 sales.
- Most recent: Gheuens Sarah (Chief Medical Officer) — Open market sale of 30,000 shares on 2026-08-04.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)34,007 sh(2 txns)
Net Shares-34,007
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer | Open market sale | 2026-08-04 | 30,000 |
| Backstrom Jay T. | Director | Grant / award | 2026-07-08 | 1,447 |
| Ballal Rahul D. | Director | Option exercise | 2026-06-18 | 2,816 |
| CAPELLO JEFFREY D | Director | Option exercise | 2026-06-18 | 2,816 |
| Foster-Cheek Kaye I | Director | Option exercise | 2026-06-18 | 2,816 |
| FOUSE JACQUALYN A | Director | Option exercise | 2026-06-18 | 2,816 |
| Ho Maykin | Director | Option exercise | 2026-06-18 | 2,816 |
| Owen Adams Catherine | Director | Option exercise | 2026-06-18 | 2,816 |
| Scadden David | Director | Option exercise | 2026-06-18 | 2,816 |
| Smith Cynthia | Director | Option exercise | 2026-06-18 | 2,816 |
| Burns James William | Chief Legal Officer | Option exercise | 2026-04-02 | 8,500 |
| Jones Cecilia | Chief Financial Officer | Option exercise | 2026-04-02 | 8,500 |
| Milanova Tsveta | Chief Commercial Officer | Option exercise | 2026-04-02 | 8,500 |
| Viswanadhan Krishnan | Chief Corp Dev & Strategy | Option exercise | 2026-04-02 | 8,100 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-04 | Gheuens Sarah | Chief Medical Officer | Open market sale | 30,000 | $30.48 |
| 2026-07-08 | Backstrom Jay T. | Director | Grant / award | 1,447 | $0.00 |
| 2026-07-01 | Gheuens Sarah | Chief Medical Officer | Option exercise | 8,375 | $0.00 |
| 2026-07-01 | Gheuens Sarah | Chief Medical Officer | Open market sale | 4,007 | $37.56 |
| 2026-06-18 | Ballal Rahul D. | Director | Option exercise | 2,816 | $0.00 |
| 2026-06-18 | CAPELLO JEFFREY D | Director | Option exercise | 2,816 | $0.00 |
| 2026-06-18 | Foster-Cheek Kaye I | Director | Option exercise | 2,816 | $0.00 |
| 2026-06-18 | FOUSE JACQUALYN A | Director | Option exercise | 2,816 | $0.00 |
| 2026-06-18 | Ho Maykin | Director | Option exercise | 2,816 | $0.00 |
| 2026-06-18 | Owen Adams Catherine | Director | Option exercise | 2,816 | $0.00 |
| 2026-06-18 | Scadden David | Director | Option exercise | 2,816 | $0.00 |
| 2026-06-18 | Smith Cynthia | Director | Option exercise | 2,816 | $0.00 |
| 2026-06-13 | Owen Adams Catherine | Director | Option exercise | 1,976 | $0.00 |
| 2026-06-13 | CAPELLO JEFFREY D | Director | Option exercise | 1,976 | $0.00 |
| 2026-04-02 | Burns James William | Chief Legal Officer | Option exercise | 8,500 | $0.00 |
| 2026-04-02 | Burns James William | Chief Legal Officer | Open market sale | 3,280 | $34.71 |
| 2026-04-02 | Gheuens Sarah | Chief Medical Officer | Option exercise | 8,500 | $0.00 |
| 2026-04-02 | Gheuens Sarah | Chief Medical Officer | Open market sale | 2,940 | $34.71 |
| 2026-04-02 | Jones Cecilia | Chief Financial Officer | Option exercise | 8,500 | $0.00 |
| 2026-04-02 | Jones Cecilia | Chief Financial Officer | Open market sale | 3,141 | $34.71 |
| 2026-04-02 | Milanova Tsveta | Chief Commercial Officer | Option exercise | 8,500 | $0.00 |
| 2026-04-02 | Milanova Tsveta | Chief Commercial Officer | Open market sale | 3,262 | $34.71 |
| 2026-04-02 | Viswanadhan Krishnan | Chief Corp Dev & Strategy | Option exercise | 8,100 | $0.00 |
| 2026-04-02 | Viswanadhan Krishnan | Chief Corp Dev & Strategy | Open market sale | 2,959 | $34.71 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:02 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-06 | 4 | 2026-08-04 | View on SEC.gov → |
| 2026-07-30 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-30 | 8-K | 2026-07-30 | View on SEC.gov → |
| 2026-07-10 | 4 | 2026-07-08 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
Recent news
Headlines about AGIO (Agios Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Form 144 AGIOS PHARMACEUTICALS For: 21 October By Investing.com
Investing.com Australia · 2026-10-21 -
Agios Pharmaceuticals Officer Sarah Gheuens Files Form 144 to Sell 1,489 Shares via Stock Option Exercise
Kalkine Media · 2026-10-21 -
An Agios (NASDAQ: AGIO) officer proposes selling about $55.9K in shares acquired by exercising options.
Stock Titan · 2026-10-21 -
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
Yahoo · 2026-10-21 -
Did Priority Review Just Shift Agios Pharmaceuticals' (AGIO) Investment Narrative?
Yahoo · 2026-10-20 -
(AGIO) Price Dynamics and Execution-Aware Positioning
Stock Traders Daily · 2026-10-20 -
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
Yahoo · 2026-10-20 -
Is Agios Pharmaceuticals (AGIO) Undervalued On Hopes For A Mitapivat FDA Decision?
Simply Wall Street · 2026-10-19
No headlines in this category right now — try “All”.